REFERENCES
1. Xiao Z, and Theroux P. Clopidogrel
inhibits platelet-leukocyte interactions and thrombin receptor agonist
peptide-induced platelet activation in patients with an acute coronary
syndrome. 2004;43:1982-8.
2. Wakabayashi S, Kitahara H, Nishi T,
Sugimoto K, Nakayama T, Fujimoto Y, et al. Platelet inhibition after
loading dose of prasugrel in patients with ST-elevation and
non-ST-elevation acute coronary syndrome. Cardiovascular
intervention and therapeutics. 2018;33(3):239-46.
3. Lee S, Vargova K, Hizoh I, Horvath
Z, Gulacsi-Bardos P, Sztupinszki Z, et al. High on clopidogrel treatment
platelet reactivity is frequent in acute and rare in elective stenting
and can be functionally overcome by switch of therapy. 2014;133:257-64.
4. Pinxterhuis TH, Ploumen EH, Zocca
P, Doggen CJM, Schotborgh CE, Anthonio RL, et al. Outcome after
percutaneous coronary intervention with contemporary stents in patients
with concomitant peripheral arterial disease: A patient-level pooled
analysis of four randomized trials. Atherosclerosis.2022;355:52-9.
5. Khalid U, Bandeali S, Jones PG,
Virani SS, Hira R, Hamzeh I, et al. Prescription Patterns of
Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary
Intervention With Stent Implantation (from the NCDR PINNACLE Registry).Am J Cardiol. 2019;124(12):1807-12.
6. Sasaki M, Mitsutake Y, Ueno T,
Fukami A, Sasaki KI, Yokoyama S, et al. Low ankle brachial index
predicts poor outcomes including target lesion revascularization during
the long-term follow up after drug-eluting stent implantation for
coronary artery disease. J Cardiol. 2020;75(3):250-4.
7. Sidhu MS, Lyubarova R, Bangalore S,
and Bonaca MP. Challenges of long-term dual antiplatelet therapy use
following acute coronary syndromes. American heart journal.2022;246:44-64.
8. Bolognese L, and Angiolillo DJ.
Unravelling the benefit against the risk of long-term dual antiplatelet
therapy. Current opinion in cardiology. 2011;26 Suppl 1:S22-30.
9. Ryu SH, Park BY, Kim SY, Park SH,
Jung HJ, Park M, et al. Regioselective hydroxylation of omeprazole
enantiomers by bacterial CYP102A1 mutants. Drug metabolism and
disposition: the biological fate of chemicals. 2014;42(9):1493-7.
10. Kang D, Geng T, Lian Y, Li Y,
Ding G, Huang W, et al. Direct inhibition of Re Du Ning Injection and
its active compounds on human liver cytochrome P450 enzymes by a
cocktail method. Biomed Chromatogr. 2017;31(7).
11. Brosen K. Pharmacogenetics of
drug oxidation via cytochrome P450 (CYP) in the populations of Denmark,
Faroe Islands and Greenland. Drug metabolism and personalized
therapy. 2015;30(3):147-63.
12. Garcia C, Maurel-Ribes A, Nauze
M, N’Guyen D, Martinez LO, Payrastre B, et al. Deciphering biased
inverse agonism of cangrelor and ticagrelor at P2Y12 receptor.Cell Mol Life Sci. 2019;76(3):561-76.
13. Wu CC, Tsai FM, Chen ML, Wu S,
Lee MC, Tsai TC, et al. Antipsychotic Drugs Inhibit Platelet Aggregation
via P2Y 1 and P2Y 12 Receptors. Biomed Res Int.2016;2016:2532371.
14. Mwinyi J, Vokinger K, Jetter A,
Breitenstein U, Hiller C, Kullak-Ublick GA, et al. Impact of variable
CYP genotypes on breast cancer relapse in patients undergoing adjuvant
tamoxifen therapy. Cancer chemotherapy and pharmacology.2014;73(6):1181-8.
15. Braun OO, Angiolillo DJ, Ferreiro
JL, Jakubowski JA, Winters KJ, Effron MB, et al. Enhanced active
metabolite generation and platelet inhibition with prasugrel compared to
clopidogrel regardless of genotype in thienopyridine metabolic pathways.Thrombosis and haemostasis. 2013;110(6):1223-31.
16. Xie X, Ma YT, Yang YN, Li XM, Ma
X, Fu ZY, et al. CYP2C19 phenotype, stent thrombosis, myocardial
infarction, and mortality in patients with coronary stent placement in a
Chinese population. PloS one. 2013;8(3):e59344.
17. Goh LL, Lim CW, Sim WC, Toh LX,
and Leong KP. Analysis of Genetic Variation in CYP450 Genes for Clinical
Implementation. PloS one. 2017;12(1):e0169233.
18. Barter ZE, Tucker GT, and
Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics
between chinese and caucasian populations predicted by mechanistic
physiologically based pharmacokinetic modelling. Clinical
pharmacokinetics. 2013;52(12):1085-100.
19. Huang X, Zhou Y, Zhang J, Xiang
H, Mei H, Liu L, et al. The importance of CYP2C19 genotype in tacrolimus
dose optimization when concomitant with voriconazole in heart transplant
recipients. British journal of clinical pharmacology. 2022.
20. Chambliss AB, Resnick M, Petrides
AK, Clarke WA, and Marzinke MA. Rapid screening for targeted genetic
variants via high-resolution melting curve analysis. Clin Chem Lab
Med. 2017;55(4):507-16.
21. Yang L, George J, and Wang J.
Deep Profiling of Cellular Heterogeneity by Emerging Single-Cell
Proteomic Technologies. Proteomics. 2020;20(13):e1900226.
22. Jabir FA, and Hoidy WH.
Pharmacogenetics as Personalized Medicine: Association Investigation of
SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a
Breast Cancer Population in Iraqi Women. Clin Breast Cancer.2018;18(5):e863-e8.
23. Mortarino M, Franceschi A,
Mancianti F, Bazzocchi C, Genchi C, and Bandi C. [Quantitative PCR in
the diagnosis of Leishmania]. Parassitologia.2004;46(1-2):163-7.
24. Bretagne S. Primary diagnostic
approaches of invasive aspergillosis–molecular testing. Med
Mycol. 2011;49 Suppl 1:S48-53.
25. Kwong KM, Tam CC, Chan R, Lee
SWL, Ip P, and Kwok J. Comparison of Single Nucleotide Polymorphism
genotyping of CYP2C19 by Loop-mediated isothermal amplification and
real-time PCR melting curve analysis. Clin Chim Acta.2018;478:45-50.
26. Krajciova L, Petrovic R, Deziova
L, Chandoga J, and Turcani P. Frequency of selected single nucleotide
polymorphisms influencing the warfarin pharmacogenetics in Slovak
population. Eur J Haematol. 2014;93(4):320-8.
27. Cooper JW. Adverse drug
reaction-related hospitalizations of nursing facility patients: a 4-year
study. South Med J. 1999;92(5):485-90.
28. Freitas AR, Tedim AP, Novais C,
Lanza VF, and Peixe L. Comparative genomics of global optrA-carrying
Enterococcus faecalis uncovers a common chromosomal hotspot for optrA
acquisition within a diversity of core and accessory genomes.Microb Genom. 2020;6(6).
29. Zhang Y, Xu L, Qiu J, Li Z, Li L,
Ren G, et al. Association between SNP rs10569304 on the second expressed
region of hole gene and the congenital heart disease. J Huazhong
Univ Sci Technolog Med Sci. 2010;30(4):430-6.